azd0022

Colorectal Cancer

AstraZenecaPhase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
MARBLE DUST James Varani	Phase 2/3	BB
Orectalip Sinphar Pharmaceutical Co., Ltd	Phase 4	BB
Eloxatin Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.	Phase 4	BB
FLUOROURACILUM UNICANCER	Phase 4	BB

View all 50 →

Same molecule, other indications

azd0022 is also rated in:

Advanced Solid TumoursDormant

CC

Indicative ·

43 / 100

non-small cell lung carcinomaDormant

C

Indicative ·

39 / 100

pancreatic ductal adenocarcinomaDormant

C

Indicative ·

39 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.